Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)

Rheumatology

Volumn 48, Issue 4, 2009, Pages 425-432

  Combe, Bernard ^a   Swergold, Gary ^b   McLay, James ^c   McCarthy, Timothy ^d   Zerbini, Cristiano ^e   Emery, Paul ^f   Connors, Laurine ^b   Kaur, Amarjot ^b   Curtis, Sean ^b   Laine, Loren ^g   Cannon, Christopher P ^h  

^a LAPEYRONIE HOSPITAL   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d Manitoba Clinic   (Canada)

^e HOSPITAL HELIÓPOLIS   (Brazil)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Analgesia; Cardiovascular safety; COX 2 inhibitors; Gastrointestinal safety; NSAIDs; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

DICLOFENAC; ETORICOXIB;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; LIVER DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RENOVASCULAR DISEASE; SIDE EFFECT; STOMACH ULCER; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; TREATMENT DURATION;

AGED; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; EMERGENCIES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; OSTEOARTHRITIS; PYRIDINES; SAFETY; SAMPLE SIZE; SULFONES; THROMBOSIS;

EID: 63249097431     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep005     Document Type: Article

References (30)

1. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15.
2. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
3. Van Hecken A, Schwartz JI, Depre M et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-20.
4. FitzGerald GA, Loll P. COX in a crystal ball: Current status and future promise of prostaglandin research. J Clin Invest 2001;107:1335-7.
5. Chauret N, Yergey JA, Brideau C et al. In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 2001;11:1059-62.
6. Matsumoto AK, Cavanaugh PF Jr. Etoricoxib. Drugs today 2004;40:395-414.
7. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
8. Farkouh ME, Kirshner H, Harrington RA et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: Randomised controlled trial. Lancet 2004;364:675-84.
9. Hunt RH, Harper S, Watson DJ et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98:1725-33.
10. Hunt RH, Harper S, Callegari P et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201-10.
11. Ramey D, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: An updated combined analysis analysis. Curr Med Res Opin 2005;21: 715-22.
12. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
13. Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
14. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006;332:1302-8.
15. Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: A meta-analysis. Arthritis Res Ther 2006;8:R153.
16. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme: A randomised comparison. Lancet 2006;368:1771-81.
17. Cannon CP, Curtis SP, Bolognese JA, Laine L. Clinical trial design and patient demographics of the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006;152:237-45.
18. Baraf HSB, Fuentealba C, Greenwald M et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: Results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial. J Rheumatol 2007;34:408-20.
19. Krueger K, Lino L, Dore R et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: Results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis 2008;67:315-22.
20. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis longterm (MEDAL) programme: A randomised comparison. Lancet 2007;369:465-73.
22. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
23. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986;42:507-19.
24. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;20;345:2009-17.
25. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987;32:1-12.
26. Brater DC. Clinical aspects of renal prostaglandins and NSAID therapy. Semin Arthritis Rheum 1988;17:17-22.
27. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991;90:42S-7S.
28. Fisher ND, Hurwitz S, Ferri C, Jeunemaitre X, Hollenberg NK, Williams GH. Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension. Hypertension 1999;34:388-94.
29. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84.
30. Curtis SP, Ng J, Yu Q et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004;26:70-83.